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A1A α-1 antitrypsin 
A2AP α-2 antiplasmin 
ACTB actin beta 
APOA1 apolipoprotein A-I 
APOA2 apolipoprotein A-II 
APOC1 apolipoprotein C-I 
APOM apolipoprotein M 
ATIII antithrombin III 
ATE arterial thromboembolism 
BCA bicinchroninic acid 
C8G complement C8 gamma chain 
CHF congestive heart failure 
CKD chronic kidney disease 
CPN1 carboxypeptidase N subunit 1 
ECM Extracellular matrix 
FDR false discovery rate 
GO Gene Ontology   
HCM hypertrophic cardiomyopathy  
HF heart failure 
HFpEF heart failure with preserved ejection fraction 
IAA idoacetamide 
IgHC immunoglobulin heavy chain 
IgL immunoglobin lambda 
IgK immunoglobin kappa 
IgG2 immunoglobin gamma-2 
IQR interquartile range 
IRIS International Renal Interest Society 
ISACHC International Small Animal Cardiac Health Council 
ITIH1 inter-alpha-trypsin inhibitor heavy chain 4 
ITIH4 inter-alpha-trypsin inhibitor heavy chain 4 
IVSd interventricular septum thickness at end diastole 
JCHAIN immunoglobin J chain 
LA left atrial 
LA/Ao LA-to-aortic root ratio 
LC-MS liquid chromatography-mass spectrometry 
LV FS left ventricular fractional shortening  
LVFWd left ventricular free wall thickness at end diastole 
MMP matrix metalloproteinase 
MRM multiple reaction monitoring 
NCBI National Center for Biotechnology Information 
NT-proBNP N-terminal pro-brain natriuretic peptide 
PF4 platelet factor 4 
PVDF Polyvinylidene Flouride 
RCM restrictive cardiomyopathy 
SEC spontaneous echo contrast 
SERPINs serine protease inhibitors 
SRM selected reaction monitoring 
TBST TBS containing 0.1 % Tween-20 
TEAB triethyl ammonium bicarbonate 
TGF-β2 transforming growth factor beta 2 
THBS1 thrombospondin 1 
TIMP tissue inhibitor of matrix metalloproteinase  
TMSB4X thymosin β-4 
TMT tandem mass tag 




Cardiomyopathies affect both cats and humans, and they can cause serious consequence such 
as congestive heart failure (CHF). To date, the pathophysiological mechanism of CHF is not 
fully understood. In this study, for the first time, we used a proteomic approach combined with 
bioinformatic analysis to evaluate serum protein change in cats with CHF. Results indicate 
systemic inflammation, coagulation protein changes, innate immunity and extracellular matrix 
remodeling are involved in feline CHF, which are largely comparable with findings in previous 
human studies. Our study provides new insights into CHF and cardiomyopathy in cats, and the 
identified novel biomarkers and pathophysiological pathways provide valuable information for 
future studies.   
  
Highlights  
• First proteomics study evaluating circulating protein change in feline CHF 
• Systemic inflammation and ECM remodeling occur in feline CHF 
• Coagulation proteins and innate immunity play a role in feline CHF 
• A list of novel biomarkers is identified and predicted 
  
Abstract  
The pathogenesis of feline cardiomyopathy and congestive heart failure (CHF) requires further 
understanding. In this study, we assessed serum proteome change in feline CHF, aiming to 
identify novel biomarker for both research and clinical use. The study comprised 15 cats in 
CHF, 5 cats in preclinical cardiomyopathy and 15 cats as healthy controls. Serum proteome 
profiles were obtained by tandem mass tag labelling followed by mass spectrometry. Protein 
concentrations in CHF cats were compared with healthy controls. Western blot was performed 
for proteomic validation. Correlations were assessed between the altered proteins in CHF and 
clinical variables in cats with cardiomyopathy to evaluate protein-cardiac association. 
Bioinformatic analysis was employed to identify pathophysiological pathways involved in 
feline CHF. Sixteen serum proteins were significantly different between CHF and healthy 
control cats (P < 0.05). These included serine protease inhibitors, apolipoproteins and other 
proteins associated with inflammation and coagulation. Clinical parameters from cats with 
cardiomyopathy significantly correlated with the altered proteins (P < 0.05). Bioinformatic 
analysis identified 13 most relevant functional profiles in feline CHF, which mostly associated 
with extracellular matrix organization and metabolism.  
Data are available via ProteomeXchange with identifier PXD017761. 
Introduction  
Cardiomyopathy is a common cardiac condition in both cats and humans. Apart from known 
genetic mutation factors responsible for certain breed disposition and familial inheritance, the 
aetiology remains unclear for the majority of idiopathic cardiomyopathy cases which usually 
occur in a later stage of life [1, 2]. While some affected cats develop terminal conditions such 
as congestive heart failure (CHF) and arterial thromboembolism (ATE) soon after diagnosis, 
others may remain asymptomatic for life [3]. The need for improved understanding in the 
disease pathogenesis is a driving force for exploring novel biomarkers for research and clinical 
use. 
Feline cardiomyopathy has been proposed as an animal disease model particularly for human 
heart failure with preserved ejection fraction (HFpEF) [4]. Both conditions are found to be 
associated with diastolic dysfunction, with decreased ventricular compliance due to myocardial 
fibrosis [5, 6]. In humans, HFpEF has been associated with systemic inflammation [7]. A recent 
theory postulated that a systemic pro-inflammatory state induced by other disorders can 
contribute to cardinal pathology in HFpEF [8]. In feline CHF, inflammatory cell infiltration 
and myocardial remodeling has consistently been seen in cardiac pathology [6, 9, 10]. One 
previous study reported circulating tumor necrosis factor-α was increased in 40% of CHF cats 
with various phenotypes of cardiomyopathy, suggesting a link between systemic inflammation 
and feline CHF [11]. Coagulation disorders have also been documented in both human and 
feline cardiomyopathy [12, 13, 15, 16]. In feline cardiomyopathy, platelet activation and 
hypercoagulation has been found more prevalent in those with advanced disease or having 
thrombotic risk/event [13, 16]. However, the pathophysiology of coagulation activation in CHF 
and cardiomyopathy in cats is far from clear. As few studies have investigated systemic 
changes in feline CHF, a global detection of circulating protein change would be useful to 
provide additional information on disease pathogenesis. 
Although proteomics is being increasingly used in veterinary and animal sciences [17, 18] there 
have been few reports of the use of this advanced protein analysis technology to study feline 
disease. In this study, we aimed to evaluate the serum proteome change in feline CHF by using 
shotgun proteomics combined with bioinformatic analysis. We hypothesized that the serum 
proteome would change in feline CHF and that novel biomarkers might be identified based on 
the differentially regulated proteins. 
Materials and Methods  
Animals and Sample Collection 
Twenty cats diagnosed with primary cardiomyopathy were enrolled in the study with full owner 
consent and ethical approval in a referral cardiology service. At admission, 15 cats were in 
CHF and 5 cats were preclinical. Cardiomyopathy and CHF diagnoses were based on 
echocardiography, thoracic radiographs and/or thoracic ultrasonographic findings. Diagnostic 
criteria for cardiomyopathies were based on previous publications [2, 19-22]. Before  
enrolment, cats with any of the following conditions were excluded; (1) secondary 
cardiomyopathy due to hyperthyroidism, acromegaly or systemic hypertension; (2) primary 
chronic kidney disease (CKD) at International Renal Interest Society (IRIS) stage II or above 
at the time of admission; (3) pre-existing inflammatory comorbidities including any active 
infectious disease, recent inflammatory events (surgery or trauma) or systemic diseases 
(pancreatitis, neoplasia and anaemia secondary to chronic inflammatory disease). A clinical 
record was collected for each cat with cardiomyopathy at the entry of the study including age, 
sex, breed, cardiomyopathy and CHF diagnoses, CHF severity, body weight, left atrial (LA) 
diameter, LA-to-aortic root (LA/Ao) ratio, left ventricular free wall thickness at end diastole 
(LVFWd), interventricular septum thickness at end diastole (IVSd), left ventricular fractional 
shortening (LV FS), spontaneous echo contrast (SEC), intra-cardiac thrombus, ATE, 
arrhythmia and comorbidities. Blood was sampled via venepuncture, followed by 
centrifugation at 5433g for 3 min, serum was separated, collected into a collection tube and 
stored at -20°C temporarily prior to transferring to -80°C for storage.  
Commercial serum samples (Biobest, UK) from 15 clinically healthy cats were used as normal 
controls. As echocardiographic exams were not performed in those cats, N-terminal pro-brain 
natriuretic peptide (NT-proBNP) assay (Cardiopet, IDEXX) was used for screening for occult 
cardiomyopathy in the healthy control population [23, 24]. All the enrolled healthy controls 
had an NT-proBNP under the detectable range (< 24 pmol/l).   
Tandem Mass Tag (TMT)-Based Quantitative Proteomics 
Protein Sample Preparation 
Total serum protein concentration of each sample was determined by using a Bicinchroninic 
Acid (BCA) protein Assay (Thermo Scientific, Rockford, USA). An internal standard control 
was prepared by pooling equal amount of protein from all samples used in the study. Prior to 
peptide labelling, protein reduction, alkylation, precipitation and digestion were performed as 
previously described [25]. In brief, for each sample and the standard control, 35 µg serum 
protein was diluted with 0.1 M triethyl ammonium bicarbonate (TEAB, pH 7.8) to a final 
volume of 50 µl. A volume of 2.5 µl of 200 mM DTT was added for protein reduction, followed 
by 1 h incubation at 55°C. Samples were alkylated by adding 2.5 µl of 375 mM idoacetamide 
(IAA) and incubation for 30 min at room temperature in the dark. Subsequently, samples were 
precipitated by adding 300 µl pre-chilled acetone at -20°C overnight. After centrifugation at 
8000 x g for 10 min at 4°C, 35 µg protein pellets were reconstituted in 50 µl of 0.1 M TEAB 
and digested with trypsin (1:40, w/w) at 37°C overnight.  
Peptide Labelling 
Tryptic peptides were labelled with TMT (Thermo Scientific), by adding 18 µl of the TMT 
labelling reagent to each digested sample and incubating for 1 h at room temperature. The 
internal standard was labelled with the TMT m/z 126 isobaric tag while the remaining 5 tags 
were allocated randomly to the samples. Labelling reaction was quenched by adding 8 µl of 5% 
hydroxylamine HCl solution (w/w) to the mixture to react for 15 min. For each experiment, 
equal amounts of 6 different TMT-modified samples (including an internal standard) were 
combined into the new tube as a final sample. The final samples were aliquoted, dried and 
stored at -80°C for further analysis.   
Liquid Chromatography-Mass Spectrometry (LC-MS)/MS 
LC-MS/MS analysis of TMT-labelled peptides was performed for protein identification and 
quantification. Dried TMT-labelled peptides were reconstituted in buffer A (2% ACN in 0.1 % 
FA) and an amount of 1 μg was loaded on the trapping column (C18 PepMap100, 5 µm, 100 
A, 300 µm x 5 mm) using Dionex Ultimate 3000 RSLS nano flow system (Dionex). All 
peptides were separated using PepMap™ RSLC C18 50 cm x 75 μm ID column with linear 
gradient 5-35% buffer B (0.1% FA in 80% ACN) over 120 min at a flow rate of 300 nl/min. 
Eluate from the column was introduced in Thermo Scientific Q Exactive Plus mass 
spectrometer by Nanospray Flex ion source and SilicaTip emitter (New Objective). The 
ionisation voltage was set to 1.9 kV and the ion transfer tube temperature at 250 °C. MS was 
operating in positive ion mode using FT HCD MS2. Full scan FTMS spectra were acquired in 
range from m/z 350.0 to 1900.0 with a resolution of 70000, AGC target value of 1 x 106 and 
the maximum injection time 110 ms. Eight most intense peaks from MS spectrum were selected 
for fragmentation, excluding the ions with the unassigned charge state, as well as +1 and more 
than +7. The HCD MS/MS scan was fixed to start from m/z 100.00 with a resolution of 17500 
using MS2 AGC target of 5 x 104. The step collision energy was set to 25, 35 and 40% NCE, 
respectively. An isolation window of ± 1.6 Da was applied to isolate precursor ions with 
dynamic exclusion of 30 s.  
MS Data Analysis 
Thermo raw files were used for SEQUEST search against National Centre for Biotechnology 
Information (NCBI) database mining Felis catus fasta files (downloaded from NCBI database 
on 15/09/2017, 44239 sequences), using Proteome Discoverer v2.0. HCD tandem mass spectra 
were used for protein identification, and TMT-sixplex relative quantification was performed 
based on reporter ion intensity ratio. The following setting was used: carbamidomethylation 
(C) peptide modification, oxidation (M) and TMT sixplex (peptide N-terminus, K) dynamic 
modification; one trypsin missed cleavage site; precursor tolerance and ion fragment tolerance 
were set at 10 ppm and 0.05 Da, respectively. At least two unique peptides and false discovery 
rate (FDR) less than 5% were required for reporting identified proteins.  
Proteomic Data Validation Using Western Blot 
Prothrombin and tetranectin were selected for the validation based on biological significance, 
research interest and antibody availability. Feline serum samples were diluted 5-fold with Tris-
HCl 50 mM pH 7.5/0.05% SDS and supplemented with 5 X Laemmli buffer {87.5mM Tris-
HCl pH 6.8, 45% Glycerol (v/v), SDS 0.5% (m/v), 0.01 % Bromophenol blue (m/v) and 12.5% 
β-mercaptoethanol (v/v)}, then heated for 10 min at 70°C. Samples were subsequently loaded 
onto an SDS PAGE gel (4% acrylamide-bisacrylamide stacking gel and 10% acrylamide-
bisacrylamide resolving gel), subjected to electrophoresis for 10 min at 90 V followed by 60 
min at 120 V. When electrophoresis stopped, wet blotting was performed on Polyvinylidene 
Flouride (PVDF) membranes (GE-Healthcare, IL, USA) for 2 h at 4 °C and 150 mA intensity. 
After blotting, membranes were blocked for 1 h using 0.2% I-blockTM Protein-Based Blocking 
Reagent (Thermo Fisher Scientific, Waltham, MA, USA) prepared in TBST {TBS containing 
0.1 % Tween-20 (Sigma-Aldrich, Taufkirchen, Germany)} at room temperature on a shaker.  
Anti-rat prothrombin and anti-human tetranectin rabbit antibodies (ab113431 and ab202134, 
Abcam, Cambridge, UK) were diluted into 1:1000 and 1:600 respectively with 0.2% I-blockTM 
Protein-Based Blocking Reagent/TBST buffer. After 1 h incubation at room temperature on a 
shaker, membranes were washed 3 times with TBST for 5 min then incubated with a secondary 
antibody (mouse anti-rabbit 1:5000 dilution, Santa Cruz Biotechnology, TX, USA) in 0.2% i-
block/TBST for 1 h at room temperature on a shaker. Subsequently, membranes were washed 
3 times with TBST for 5 min, then dried and covered with luminol reagent (Santa Cruz 
Biotechnology, TX, USA) to react for 5 min at room temperature. Chemiluminescence imaging 
was performed in an Odyssey chemiluminescence and fluorescence imager (LI-COR 
Biosciences, Lincoln, NE, USA). Protein blots were stained with Ponceau S solution (Sigma-
Aldrich, Taufkirchen, Germany) for obtaining total proteins in each sample, protein band 
intensities were subsequently quantified using Image J software (National Institutes of Health, 
USA). For comparing the target protein concentrations in CHF and in the healthy control group, 
semi-quantification was performed by normalizing the target proteins to total proteins in each 
sample, then mean values of CHF/healthy control group were calculated.  
Statistical Analysis  
Prior to statistical analysis, peptides were filtered out if not detected in more than 75% of 
samples. Subsequently the remaining peptides were grouped at the protein level. Outliers were 
detected by using boxplots and were excluded for statistical analysis. Due to non-normal 
distribution of data, differentially regulated proteins between CHF and healthy controls were 
analysed with Wilcoxon test, followed by Bonferroni test to adjust p-value. Correlations 
between  relative intensity ratios (i.e. original MS intensities normalized to the internal standard 
controls) of the differential proteins and clinical variables were determined using Spearman 
rank test. Following using Shapiro-Wilk tests confirmed data normality distribution, Student t-
tests were performed to compare age, weight, echocardiography parameters, NT-proBNP data 
and protein validation data among the CHF, preclinical cardiomyopathy and the healthy control 
groups. R Software (version 3.3.1) (R core team) and Microsoft Office Excel (Microsoft, USA) 
was used for above analyses. Statistical significance was defined as P < 0.05. 
Bioinformatic Analysis 
Followed the statistical analyses, from those proteins differentially regulated, Gene Ontology 
(GO) analyses were performed using a previously published approach [26] to determine the 
GO terms for proteins over or under-expressed in CHF (Figure 1). For each GO terms, the full 
list of proteins/genes/chemicals and their interactions were downloaded from Reactome.org. 
Following initial analyses, a further GO enrichment was performed to generate a better 
interactome for a deeper view of GO terms based on the initial set of markers and their first 
interactors. Clusterization was performed to group proteins sharing strongest interactions. GO 
analyses were performed in each protein cluster as well as in the unclustered proteins. Based 
on similarity of GO terms and their nodes, positions of GO terms were calculated by Cytoscape 
algorithms. Once the most global overview was obtained, a list of best candidate markers was 
proposed based on protein interactions with different GO terms. 
Results  
Study population 
Clinical information of the study populations is summarized in Table 1 and Figure 2. There 
was no significant difference in age among the three cat groups. There were more male cats in 
all three groups. Serum NT-proBNP clearly differentiated the three groups. Median NT-
proBNP concentration was 1500 pmol/l {interquartile range (IQR) 1180-> 1500} in CHF cats; 
119 pmol/l (IQR 69-254) in preclinical cats and < 24 pmol/l in the healthy controls. There was 
no further clinical data available for the healthy controls. Body weight was not significantly 
different between the CHF and preclinical cats. LA diameter and LA/Ao ratios were higher in 
the CHF cats compared to the preclinical cats (P < 0.001). There no differences observed in 
left ventricle echo variables i.e. LVFWd, IVSd and LV FS between the CHF and preclinical 
groups. Comorbidities recorded in CHF cats were: stable diabetes mellitus (n = 1), suspected 
abdominal carcinomatosis (n = 1), mild to moderate anaemia (n = 2); and in the preclinical cats 
were: chronic cervical mass (n = 1) and eosinophilia from unknown origin (n = 1).  
All CHF cats were in International Small Animal Cardiac Health Council (ISACHC) 
Classification IIIa (n = 7) or IIIb (n = 8), with various clinical presentations including pleural 
effusion (n = 11), pulmonary oedema (n = 8), pericardial effusion (n = 3) and ascites (n = 3). 
They received different combinations of the following cardiac medications: furosemide, 
torasemide, pimobendan, benazepril, spironolactone, clopidogrel, aspirin and diltiazem. Eight 
cats in CHF were at risk of thrombotic events, 7 had SEC and 1 had an intra-cardiac thrombus. 
The following arrhythmias were identified in the CHF population: ventricular premature 
complex (n = 9); atrial fibrillation (n = 3); anterior fascicular block (n = 2); atrial premature 
complex (n = 1) and ventricular tachycardia (n = 1). There were no arrhythmias noted in the 
preclinical group.  
Serum proteome profile comparison in CHF, healthy control and preclinical cats 
Initially 439 peptides were detected by the TMT mass spectrometry and the LC-MS/MS spectra 
from the healthy and CHF feline groups have been archived by submitting to PRIDE archive 
via ProteomeXchange Consortium via the PRIDE [27] partner repository with the dataset 
identifier PXD017761. After eliminating those peptides with substantial undetected data, 271 
peptides remained. After applying the filtering criteria i.e. unique peptide number ≥ 2 and FDR 
< 5%, 116 different proteins were identified (Supplementary Table 1) and analysed statistically.  
In total 16 serum proteins were found significantly altered (P < 0.05) in the feline CHF group 
compared to the healthy controls. Among them, 11 proteins were increased in the CHF group 
(Table 2), including serine protease inhibitors (SERPINs) {i.e. α-1 antitrypsin (A1A), 
antithrombin III (ATIII), α-2 antiplasmin (A2AP) and C1 inhibitor}, apolipoproteins {i.e. 
apolipoprotein A-II (APOA2) and apolipoprotein M (APOM)}, carboxypeptidase N subunit 1 
(CPN1), ceruloplasmin, platelet factor 4 (PF4), prothrombin and thymosin β-4 (TMSB4X). 
Five protein concentrations were significantly lower in the feline CHF group compared to the 
healthy controls (Table 3), these were immunoglobins {i.e. immunoglobulin heavy chain 
(IgHC), immunoglobulin kappa (IgK) and immunoglobulin lambda (IgL)}, complement C8 
gamma chain (C8G) and tetranectin. Protein relative intensities from individual cats are 
summarized in Supplementary Table 2. 
Although not statistically significant, another 11 proteins showed trends of increase or decrease  
in the CHF group compared to healthy controls (P < 0.1). These were used in later 
bioinformatic pathway analysis in addition to the significantly regulated proteins. There were 
6 proteins showed an up-regulated trend, including inter-alpha-trypsin inhibitor heavy chain 4 
(ITIH4) (P = 0.092), complement C4-A (P = 0.07), vitamin D-binding protein (P = 0.062), 
apolipoprotein A-I (APOA1) (P = 0.074), apolipoprotein C-I (APOC1) (P = 0.054) and 
thrombospondin 1 (THBS1) (P = 0.052). Five proteins showed a decrease trend, including actin 
beta (ACTB) (P = 0.086), immunoglobin gamma-2 (IgG2) heavy chain (P = 0.098), inter-
alpha-trypsin inhibitor heavy chain 1 H (ITIH1) (P = 0.060), immunoglobulin J chain (JCHAIN) 
(P = 0.097) and vitronectin (P = 0.081).  
Among all the altered proteins, tetranectin was significantly higher in preclinical 
cardiomyopathy compared to healthy controls and CHF cats (P < 0.05). For the rest of the 
proteins, the concentrations in the preclinical group were either similar to healthy control or 
CHF, or in between the two groups. 
Validation of proteomic results by Western Blot 
Serum prothrombin was detected by Western blot in CHF and healthy control cats (n = 10 
respectively) (Figure 3). Two distinct protein bands were detected at 72 kDa and 24 kDa 
respectively. Semi-quantification results showed prothrombin level was higher in CHF group 
compared to healthy controls, although the change was not statistically significant. Variable 
prothrombin levels were seen in each group. On tetranectin immunoblots, weak distinct bands 
between 15 kDa and 24 kDa were detected, similar to prothrombin, overall tetranectin 
concentrations were higher in the healthy control samples than in the CHF group, however, the 
concentrations varied within each group (data not shown). 
Correlations of the differentially regulated proteins and clinical variables in cats with 
cardiomyopathy 
In the CHF population, proteins that were altered in CHF showed significant correlations with 
echo parameters (P < 0.05) (Table 4-A). The SERPINs ATIII, A2AP and C1 inhibitor were 
found positively correlated with LV FS, and ATIII showed a moderate positive correlation with 
LVFWd. APOA2 also showed a moderate positive correlation with LVFWd. The presence of 
SEC was found positively correlated with IGHC.  
When the cats with preclinical cardiomyopathy were included (Table 4-B), ATIII and APOA2 
remained positively correlated with LVFWd (P < 0.05). SERPIN A1A showed significant 
positive correlation with NT-proBNP in the combined groups cardiomyopathy population (r = 
0.69, P < 0.01). Positive correlations were also identified between APOM and LA/Ao, PF4 and 
LV FS, A2AP, C8G and LVFWd (P < 0.05). ATIII and A2AP showed negative correlations 
with body weight (P < 0.05).  
GO pathway analysis 
Due to the lack of available database in feline species, Homo sapiens ortholog was used for 
bioinformatics analysis. From those proteins which showed differential serum concentrations 
in feline CHF compared to normal cats (P < 0.1), initial GO analysis revealed 4 over-expressed 
pathways (GO terms) based on the Reactome pathway database (Reactome.org). These were 
platelet degranulation, complement cascade, formation of fibrin clot and plasma lipoprotein 
assembly. The terms were all identified from the up-regulated proteins in CHF, no term was 
detected in the down-regulated proteins due to insufficient protein number. Subsequent 
enrichment generated a network which included 473 protein nodes and 5433 interactions. Ten 
clusters and one unclustered protein group were identified in the enriched network, GO analysis 
of the clusters revealed 19 GO terms. For each of the 19 GO terms, a full list of 
proteins/genes/chemicals and their interactions were identified in Reactome database, which 
generated a complete network. The final GO analysis on the global network detected 23 GO 
terms (Figure 4). Cytoscape calculation revealed three most dominant GO terms groups (Figure 
5), which were (1) extracellular matrix (ECM) organization and metabolism; (2) plasma 
vesicles and transport and (3) immune/wound system against altered cells. For the proteins 
showing differential concentrations in CHF and the proteins interacting with GO term in the 
complete network, protein cell location was examined, and most proteins were in the 
extracellular space. Additionally, 264 genes had at least 2 degree of interaction with the GO 
terms, 21 genes had at least 4 degree of GO term interaction and they were considered as best 
potential candidate gene markers based on prediction. They were FURIN, ELANE, FN1, VTN, 
A2M, COL18A, COL7A1, FGA, FGB, FGG, HSPG2, ITGAV, ITGB1, ITGB3, PLG, PROS1, 
SERPING1, TGFβ-1, TGFβ-2, TGFβ-3 and VWF.  
Discussion  
Current results showed that serum protein profile alters in cats with CHF due to primary 
cardiomyopathy compared to healthy controls. By using proteomic techniques, we detected 27 
proteins differentially regulated in feline CHF. They were associated with inflammation, 
coagulation, lipid metabolism and immune system. Some of these proteins such as the 
SERPINs were significantly correlated with clinical cardiac variables in cats with CHF and 
cardiomyopathy, supporting their involvement in the disease. Others such as TMSB4X and 
tetranectin may be involved in regulating myocardial remodeling features in feline 
cardiomyopathy including myocardial disarray, interstitial fibrosis and angiogenesis [9, 28], 
based on previous studies of these markers in other species. Bioinformatic analysis provided a 
global view of the deregulated proteins and relevant biological pathways were primarily 
associated with ECM remodeling and metabolism, innate immunity and plasma vesicles and 
transport.   
The complex relationship between heart failure (HF) and inflammation has been postulated to 
be bidirectional in humans. Systemic or local inflammation can trigger pathological remodeling 
in HF including cardiomyocyte apoptosis, maladaptive hypertrophy, endothelial dysfunction 
and ECM remodeling, whilst a decompensated heart in return can cause inflammation by 
locally releasing pro-inflammatory cytokines or through haemodynamic response [7, 29]. 
Coagulation, fibrinolysis and complement cascades play a key role in circulatory inflammatory 
response in cardiovascular disease [30, 31]. Coagulation and fibrinolytic activation has been 
reported both in feline and human cardiomyopathy [12-15], while complement activation has 
been observed in human HF and canine dilated cardiomyopathy [32-34] but not be confirmed 
in feline CHF or cardiomyopathy. 
In this study, most of the differentially regulated proteins in CHF cats have either pro- or anti- 
inflammatory properties, which are mainly involved in coagulation, fibrinolytic and 
complement pathways. Most of the proteins showed small changes in the mean value 
comparison, which is likely affected by small sample size and presence of abundant proteins. 
However, the results still supported that some of those proteins carry biomarker potential for 
feline CHF and cardiomyopathy. Validation of the proteomic results is an important part of the 
interpretation of results with Western blotting being a useful method for this purpose.  However 
for a species such as the cat, where antibodies to feline antigens are not generally available, 
this can be problematic. In this study the Western blot using antibody to rat prothrombin was 
able to demonstrate the validity of the proteomic result for this protein. The Western blot using 
antibody to human tetranectin gave only faint banding and a feline specific antibody would be 
needed for clearer results. Similarly, a human A1A antibody (Cat No. 702047, Invitrogen) has 
also been tested in the Western blot, but was demonstrated not suitable for feline samples. 
In this study over 50% of recruited CHF cats were in a pro-thrombotic state which was 
demonstrated by echocardiography i.e. SEC. Although in the correlation analysis, none of the  
upregulated coagulation proteins identified were associated with the incidence of SEC, 
interestingly, ATIII, A2AP and PF4 showed significant positive correlations with LVFWd and/ 
or LV FS, suggesting these markers might be related to left ventricular myocardial remodeling 
and function in feline cardiomyopathy. The roles of these coagulation proteins in feline CHF 
are yet to be defined, but they could represent interesting candidates for future research.  
C1-inhibitor is an extracellular protease inhibitor known to have anti-inflammatory effect by 
preventing the initial step of complement activation [35]. In this study, it had 1.4 fold increase 
in CHF cats compared to healthy controls. Its coding gene SERPING1 was also identified as a 
candidate biomarker with high probability in the bioinformatics prediction. Similar to ATIII 
and A2AP, C1 inhibitor was also positively correlated with LV FS in CHF cats, which indicated 
the SERPINs may be associated with cardiac systolic function in CHF cats. Previously, C1-
inhibitor was found to have a cardioprotective effect in a feline myocardial ischemia and 
reperfusion model [36]. By locally inhibiting neutrophil-endothelial interaction, it preserved 
endothelial function. In humans, localized increase of C1 inhibitor was observed in damaged 
cardiomyocyte following acute myocardial injury, which suggested its endogenous regulation 
of myocardial inflammation [37]. C1 inhibitor increase was also seen in acute HF in humans, 
the authors postulated it worked as an acute phase protein reflecting the inflammatory response 
[38].  
Alpha-1 antitrypsin has an anti-inflammatory effect in lung tissue by inhibiting neutrophil 
elastase and plasminogen activators to avoid excessive tissue damage [39]. Serum A1A was 
significantly higher in CHF cats, and this finding was consistent with a published human study 
in which circulating A1A was found increased in HF patients [40]. Interestingly, this proteinase 
inhibitor also showed close positive correlation to serum NT-proBNP level in cats with 
cardiomyopathy. Similarly, in human HF, A1A was found significantly correlated with BNP 
level and its increase was correlated with HF progression [41]. It is known A1A oxidation 
occurs in human HF regardless of primary aetiology, and due to the loss of its elastase 
inhibition ability, the oxidized A1A can cause endothelial dysfunction and thus cell death [42]. 
It was proposed to be an oxidative-stress related biomarker in HF and also a potential 
therapeutic target for the condition [43]. 
Ceruloplasmin is a copper binding protein which increases in the acute phase response [44].  
In the current study, it increased in CHF cats compared to healthy controls. This finding was 
consistent with the results from our previous study using a different methodology and a larger 
study population [45]. In human HF patients, higher ceruloplasmin level is associated with 
poorer clinical outcomes [46]. It was found to affect ferroxidase I activity and nitric oxide 
plasma concentration, and this may explain its pathogenetic role in HF [47, 48].  
Thymosin β-4 had a 2.8-fold increase in CHF cats compared to the healthy control, although it 
was only detectable in 33% CHF cats and in 46% healthy controls. TMSB4X is known to be 
anti-inflammatory and it promotes tissue regeneration in the wound healing process [49]. In 
human fetal heart, TMSB4X was detected in vascular endothelium, endocardium and 
epicardium, suggesting its involvement in cardiac tissue development [50]. Other evidence has 
suggested TMSB4X has a cardiac-protective property and is involved in cardiac repair via 
interaction with vascular endothelium [51]. Clinical trials with TMSB4X have been conducted 
for treating human myocardial infarction [52]. The role of TMSB4X in feline CHF and 
cardiomyopathy is not clear yet, however, given the fact that adverse myocardial remodeling  
is common in feline cardiomyopathy and CHF, TMSB4X may be a potential therapeutic 
candidate for repairing myocardial damage in cats.  
Tetranectin is a glycoprotein binding to the kringle 4 part of plasminogen. It was postulated to 
be a regulator of fibrinolysis and proteolysis in connective tissue [53, 54]. In this study, 
tetranectin was a distinct marker which was highest in preclinical cats compared to the other 
groups, but lowest in the CHF cats. The role of tetranectin in cardiovascular disease is not clear 
yet. In a coronary artery disease study, while serum tetranectin decreased, a local increase of 
tetranectin was found in the atherosclerotic arteries and correlated to the disease severity [55]. 
The systemic reduction of tetranectin might have been a result of endogenous recruitment to 
atherosclerosis lesions. It could be hypothesized that tetranectin and plasminogen activation 
may have a direct impact on myocardial remodeling during cardiomyopathy and CHF. In a 
multi-biomarker risk stratification study, lower circulating tetranectin was found to be 
associated with adverse events in human cardiovascular disease [56]. This marker has excellent 
potential as a prognostic marker for feline cardiomyopathy cases and warrants further 
investigation. 
In previous studies, leptin and fatty acid profile has been found altered in feline hypertrophic 
cardiomyopathy (HCM) [57, 58]. In our study, apolipoproteins APOA2, APOM, APOA1 and 
APOC1 were found increased in CHF cats compared to healthy controls, which supports 
altered lipid metabolism in CHF in feline cardiac disease. Generally, the role of apolipoproteins 
in cardiovascular disease has been considered beneficial. This is possibly due to their 
association with high density lipoprotein or inflammation based on previous in vitro and in vivo 
studies in humans [59-62]. More recently, increased APOM was found to be associated with 
better survival in human CHF, which was postulated possibly due to its cardiomyocyte 
protection effect through the Akt pathway [63]. In the future, a more comprehensive profile of 
lipoprotein metabolism could be evaluated in feline cardiomyopathy, such a profile would 
include lipoprotein-cholesterol concentration, apolipoprotein concentration and the activity of 
the key enzymes involved in lipoprotein metabolism [64]. 
The role of innate immunity in HF has attracted considerable attention recently, and 
immunomodulation has been considered as a therapeutic approach in regulating inflammatory 
cytokines in HF [65]. In a human study using intravenous immunoglobin in HF management, 
a positive outcome was achieved for patients on long term supplement [66]. In our study, lower 
immunoglobulins were observed in the CHF group compared to the healthy controls, which 
may indicate an ‘overuse’ of circulating immunoglobin in the disease process. It should be 
noted that the commercial healthy control serums were collected for antibody titre purpose post 
rabies vaccination, which might be another explanation for the higher immunoglobin levels in 
healthy controls compared to the CHF group.  
Bioinformatics analysis is powerful for biological pathway identification from proteomic data. 
In the current study, the final GO pathway analysis suggests ECM remodeling is a major event 
in feline CHF due to cardiomyopathy, which is consistent with previous studies from others 
[10, 57]. Aupperle and colleagues detected significantly increased concentrations of 
transforming growth factor beta 2 (TGF-β2), matrix metalloproteinase (MMP)-2 and tissue 
inhibitor of matrix metalloproteinase (TIMP)-2 in diseased feline myocardium [10]. In another 
study, TIMP-1 and MMP-3 transcripts were found significantly higher in hearts of HCM cats 
compared to the controls [28]. The same markers were also identified in our biomarker 
prediction list. Together with the two other significant aspects identified: ‘immune/wound 
against altered cells’ and ‘plasma vesicle and transport’, it could be postulated that an injury-
repair process may occur in in cats with advanced cardiomyopathy. Recently, inflammatory 
cell infiltration has been associated with ECM remodeling in feline cardiomyopathy [9, 28], 
for example, local macrophages have been proposed to be a driving factor for myocardial 
remodeling in feline HCM, and together with damaged cardiomyocytes, they may contribute 
to myocardial interstitial fibrosis by releasing inflammatory and profibrotic cytokines [28]. In 
this study, however, it remains unknown whether the systemic increase of ECM remodeling 
profile is a cause or consequence of local cardiac changes. 
There are several limitations of this study, but it does highlight the potential for use of 
proteomics to study feline disease. Firstly, this is a pilot biomarker study at discovery phase, 
future work would be necessary for further verification and validation. Current Western blot 
validation was limited due to antibody availability and optimization, more optimal validation 
methods could be explored in future studies. Using a recombinant feline protein as a positive 
control in future antibody-based validation would be helpful to establish the cross-reaction 
information when using antibodies for other species. To by-pass the use of antibodies, 
bioanalytical validation using selected reaction monitoring (SRM)/multiple reaction 
monitoring (MRM) targeted proteomic approaches could be used. However, unlike antibody-
based methods, it has not been robustly applied for clinical application due to sensitivity issues 
[67, 68]. In this study, validation tests were focused on the protein markers derived from the 
initial proteomic results, biomarkers with high degree prediction from the GO analysis would 
also be interesting to investigate and validate in future work. Regarding the study populations, 
only a small number of cats were recruited, particularly the preclinical group. For the clinically 
recruited cats with cardiomyopathy, comorbidities and therapeutic effects were not assessed, 
which were possible confounders of current results; LV FS was assessed in the current study 
as a left ventricular systolic function marker, however, it should be noted that it is not ideal 
especially if left ventricular hypertrophy is present. For the healthy controls, clinical 
information was limited, and the occult cardiac disease was screened by cardiac biomarker NT-
proBNP rather than echocardiography. For the proteomic techniques, current setting of FDR 
was 5%, which may compromise the numbers of biomarker detected in the study. The dynamic 
protein range could be an issue as we did not deplete the serum abundant proteins such as 
albumin in this study, which would lose low abundance proteins such as classic cardiac 
biomarkers NT-proBNP and troponin [69]. Future work combined with high abundance protein 
depletion would be necessary for detecting low abundance protein targets. Survival analysis 
was not performed in the current study, it would be interesting to investigate correlations 
between the identified biomarkers and event of death in future larger scale study, to determine 
whether these biomarkers can predict the risk of death in feline CHF and cardiomyopathy. 
Conclusion  
Overall, the results suggest systemic inflammation, coagulation protein changes, innate 
immunity and ECM remodeling occur in feline CHF and there are complex links between them. 
These findings bridged the gap between current understanding of pathogenesis in human and 
feline HF due to cardiomyopathy. The novel biomarkers identified in this study warrant further 
investigation for establishing their roles in disease pathogenesis and clinical use. 
Supplementary data 
The LC-MS/MS spectra from the healthy and CHF feline groups have been archived by 
submitting to PRIDE archive via ProteomeXchange with the dataset identifier PXD017761. 
Additionally, the full list of proteins identified in the feline plasma samples are provided in the 
supplementary data. 
PRIDE repository Reviewer account details: 
Username: reviewer25571@ebi.ac.uk 
Password: uU7Gtrd6  
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Table 1: Clinical information of the study population. 
 CHF (n = 15) PrC(n = 5) Nor (n = 15) 
Age (years)  6.1 (IQR 4.9-11.2) 8 (IQR 4.6-11.5) 5.3 (IQR 3.5-5.9) 
Sex Female (n = 4) 
Male (n = 11) 
Female (n = 1) 
Male (n = 4) 
Female (n = 7) 
Male (n = 8) 
Breed DSH (n = 13); Ragdoll (n = 1); 
Sphinx variant (n = 1) 
DSH (n = 4); BSH (n = 1)  
 
 
CM Diagnosis  HCM (n = 5); RCM (n = 3); 
UCM (n = 7) 
HCM (n = 5)  
Weight (kg) 4.5 (IQR 3.6-4.8) 5.2 (IQR 5.2-7.2)  
LA Diameter (mm) 20 (IQR 17-22.5) 13 (IQR 12-15)  
LA/AO ratio 2.5 (IQR 1.9-2.6) 1.34 (IQR 1.27-1.41)  
LVFWd (mm) 6.5 (IQR 5.3-7.4) 6.21 (IQR 4.34-6.29)  
IVSd (mm) 5.7 (IQR 4.7-7.5) 5.32 (IQR 5.14-8.1)  
LV FS% 27 (IQR 22-40) 52 (IQR 34-54)  
For healthy controls, only age and sex information were available. CHF, congestive heart failure; PrC, preclinical; Nor, normal healthy controls; IQR, 
interquartile range; DSH, domestic short hair; BSH, British short hair; CM, cardiomyopathy; RCM, restricted cardiomyopathy; UCM, unclassified 
cardiomyopathy; LA, left atrial; LA/AO, left atrial to aortic root ratio; LVFWd, left ventricular free wall thickness at end diastole; IVSd, interventricular septum 
thickness at end diastole; LV FS, left ventricular fraction shortening. 
Table 2: Significantly up-regulated proteins in CHF cats compared to healthy controls  (n = 15 in each group) 




Fold Change  Detectable Samples   P-value  
755822186 A1A SERPIN A1 41.1 16 1.1 30 0.024 
410958740 APOM APOM 23.4 5 1.1 30 0.038 
755776692 CPN1 CPN1 7.2 3 1.3 22 0.048 
410985907 AT III SERPIN C1 56.3 23 1.1 30 0.028 
410973663 prothrombin F2 48.2 21 1.1 30 0.002 
1126453607 Ceruloplasmin CP 41.4 36 1.1 30 0.042 
1126474650 A2AP SERPIN F2 21.7 9 1.1 30 0.042 
755812005 TMSB 4X TMSB 4X 29.5 2 2.8 12  0.008 
410986627 APOA2 APOA2 60 6 1.3 30 0.007 
755722705 PF4 PF4 16.3 2 1.3 30 0.012 
587002983 C1 inhibitor SERPING1 17.6 8 1.4 30 0.001 
CHF, congestive heart failure; A1A, α-1 antitrypsin; SERPIN A1, serine protease inhibitor family A member 1; APOM, apolipoprotein M; CPN1, 
carboxypeptidase N subunit 1; AT III, antithrombin III; SERPIN C1, serine protease inhibitor family C member 1; F2, coagulation factor II; CP, 
ceruloplasmin; A2AP, α-2 antiplasmin; SERPIN F2, serine protease inhibitor family F member 2; TMSB 4X, thymosin β-4; APOA2, apolipoprotein A-II; 
PF4, platelet factor 4; SERPIN G1, serine protease inhibitor family G member 1. 
 
Table 3: Significantly down-regulated proteins in CHF cats compared to healthy controls (n = 15 in each group) 




Fold Change  Detectable Samples P-value  
410950994 tetranectin CLEC3B 28.2 5 0.9 26 0.045 
325651605 IgHC variable region subgroup 3 IGHC 42.6 4 0.8 30 0.032 
6456731 IgK light chain IGK 44.2 8 0.8 30 0.010 
1126466567 IgL-like polypeptide 5 IGL 49.8 8 0.8 30 0.012 
587009725 C8G C8G 36.3 6 0.9 30 0.021 
CHF, congestive heart failure; CLEC3B, C-Type Lectin Domain Family 3 Member B; IGHC, immunoglobulin heavy chain; IGK, immunoglobulin kappa; 
IGL, immunoglobulin lambda; C8G, complement C8 gamma chain.  
 
Table 4-A Significant correlations between clinical variables and protein biomarkers in CHF 
population only (n = 15).  
  ATIII A2AP APOA2 C1 inhibitor IGHC 
LVFWd 0.56*   0.63*      
LV_FS% 0.67***  0.55*    0.65**    
SEC         0.65**  
ATIII, antithrombin III; A2AP, α-2 antiplasmin; APOA2, apolipoprotein A-II; IGHC, immunoglobulin 
heavy chain variable region subgroup 3; LVFWd, left ventricular free wall thickness at end diastole; 
LV FS, left ventricular fraction shortening; SEC, spontaneous echo contrast. *indicates statistical 
significance with P value <0.05; ** indicates P value <0.01. Spearman test was used to evaluate 
statistical significance. 
 
Table 4-B Significant correlations between clinical variables and protein biomarkers in combined 
CHF and preclinical cardiomyopathy groups (N = 20). 
  A1A APOM ATIII A2AP APOA2 PF4 C8G 
BW     -0.48*  -0.45*        
NT-proBNP 0.69**              
LA/Ao   0.49*            
LVFWd     0.47*  0.47*  0.61**    -0.51*  
LV_FS%           0.49*    
A1A, α-1 antitrypsin; APOM, apolipoprotein M; ATIII, antithrombin III; A2AP, α-2 antiplasmin; PF4, 
platelet factor 4; C8G, complement C8 gamma chain; BW, body weight; NT-proBNP, N-terminal-pro 
brain natriuretic peptide; LA/Ao, left atrial to aortic root ratio; LVFWd, left ventricular free wall 
thickness at end diastole; LV FS, left ventricular fraction shortening.*indicates statistical significance 








Figure 1. Schematic diagram of gene ontology (GO) analyses.  
GO analyses were performed based on the differentially regulated proteins in CHF. Subsequent 
enrichments were performed to get the most global view of the network, additional candidate 





Figure 2. Serum NT-proBNP in three cat groups.  
NT-proBNP clearly differentiated the CHF cats (n = 11) from preclinical cats (PrC) (n = 5) and 
healthy controls (Nor) (n = 15). Four CHF cats had no NT-proBNP measurements due to a 
sample limitation. *** indicates a statistical significance P < 0.001; * indicates a statistical 





Figure 3. Serum prothrombin detection in CHF and healthy controls by using Western blot.  
Prothrombin was detected in CHF and healthy control (Nor) feline serum samples (n=10 
respectively), examples of protein band pattern (n=5 for each group respectively) were 
demonstrated in protein blot. The blot showed distinct prothrombin band (size around 72kD, 
consistent with predicted band on datasheet) and a non-specific band (size around 24kD, 
suspected to be a cleaved protein product). After normalized with Ponceau S total protein 
staining, the semi-quantification results showed no statistical significance in prothrombin 
concentrations between the two groups (P>0.01). Although median levels of prothrombin and 





Figure 4. Final GO Enrichment analysis.  
The complete network analysis identified 13 most relevant functional profiles in CHF cats, 
mostly associated with extracellular matrix remodeling. Based on GO results, 246 potential 






Figure 5. Complete GO network involved in feline CHF. 
 
 
Supplementary Table 1. Full list of 116 identified proteins in cat serum 




586997898 PREDICTED: fibronectin isoform X7 [Felis catus] 70 70 42.9264 
586986149 PREDICTED: complement C4-A [Felis catus] 67 67 53.70052 
1126436109 PREDICTED: LOW QUALITY PROTEIN: pregnancy 
zone protein-like [Felis catus] 
67 67 57.77778 
586991840 PREDICTED: alpha-2-macroglobulin [Felis catus] 66 61 65.22034 
1126406397 PREDICTED: complement C3-like [Felis catus] 85 56 67.52513 
1126453965 PREDICTED: serotransferrin [Felis catus] 53 51 69.20904 
410955758 PREDICTED: apolipoprotein B-100 [Felis catus] 44 44 11.14614 
1126453607 PREDICTED: ceruloplasmin isoform X2 [Felis catus] 36 36 41.40481 
586987778 PREDICTED: plasminogen [Felis catus] 36 36 58.00493 
1126406395 PREDICTED: complement C3-like [Felis catus] 76 35 62.02532 
1126420349 PREDICTED: afamin [Felis catus] 31 31 55.57404 
586984640 PREDICTED: vitamin D-binding protein [Felis catus] 28 28 67.08861 
410963161 PREDICTED: inter-alpha-trypsin inhibitor heavy chain 
H2 [Felis catus] 
28 28 30.23256 
755765069 PREDICTED: inhibitor of carbonic anhydrase-like [Felis 
catus] 
30 28 54.44126 
755767178 PREDICTED: apolipoprotein A-I [Felis catus] 25 25 76.69173 
755784610 PREDICTED: complement C5 isoform X1 [Felis catus] 25 25 16.07143 
587018338 PREDICTED: C4b-binding protein alpha chain [Felis 
catus] 
23 23 51.08514 
410985907 PREDICTED: antithrombin-III [Felis catus] 23 23 56.25 
410978975 PREDICTED: LOW QUALITY PROTEIN: gelsolin 
[Felis catus] 
23 23 34.14322 
755767173 PREDICTED: apolipoprotein A-IV [Felis catus] 22 22 66.75393 
1126471858 PREDICTED: complement C5-like isoform X1 [Felis 
catus] 
22 22 32.89474 
312147375 haptoglobin precursor [Felis catus] 21 21 45.82133 
410973663 PREDICTED: prothrombin [Felis catus] 21 21 48.23151 
1126489264 PREDICTED: complement factor H isoform X1 [Felis 
catus] 
21 21 32.44681 
755747228 PREDICTED: pregnancy zone protein [Felis catus] 26 21 22.66576 
1126467206 PREDICTED: heparin cofactor 2 [Felis catus] 21 21 48.58871 
410951365 PREDICTED: inter-alpha-trypsin inhibitor heavy chain 
H1 [Felis catus] 
21 21 25.82418 
410958796 PREDICTED: complement factor B [Felis catus] 20 20 33.50717 
1126402137 PREDICTED: complement component C7 isoform X3 
[Felis catus] 
19 19 26.90864 
410970797 PREDICTED: kininogen-1 isoform X1 [Felis catus] 19 19 45.90164 
410956438 PREDICTED: clusterin [Felis catus] 18 18 43.62416 
1126452740 PREDICTED: histidine-rich glycoprotein isoform X2 
[Felis catus] 
17 17 32.28782 
586978046 PREDICTED: inter-alpha-trypsin inhibitor heavy chain 
H3 [Felis catus] 
17 17 29.62963 
755822186 PREDICTED: alpha-1-antitrypsin-like [Felis catus] 16 16 41.05505 
410973069 PREDICTED: hemopexin [Felis catus] 16 16 37.71552 
755722459 PREDICTED: complement factor I isoform X3 [Felis 
catus] 
15 15 32.89037 
1126402180 PREDICTED: complement component C9 [Felis catus] 15 15 31.31673 
3402547 IgM heavy chain, partial [Felis catus] 15 14 46.71202 
1126412335 PREDICTED: attractin isoform X1 [Felis catus] 14 14 9.567682 
1126479244 PREDICTED: alpha-1B-glycoprotein [Felis catus] 13 13 45.01845 
1126477106 PREDICTED: beta-2-glycoprotein 1 [Felis catus] 13 13 46.66667 
1351908 RecName: Full=Serum albumin; AltName: Allergen=Fel 
d 2; Flags: Precursor 
68 12 88.48684 
1126402123 PREDICTED: complement component C6 [Felis catus] 12 12 12.64737 
755731552 PREDICTED: vascular non-inflammatory molecule 3 
isoform X1 [Felis catus] 
12 12 30.70866 
586999703 PREDICTED: alpha-2-HS-glycoprotein [Felis catus] 12 12 51.80055 
755796073 PREDICTED: LOW QUALITY PROTEIN: 
apolipoprotein E [Felis catus] 
11 11 44.65649 
755774684 PREDICTED: angiotensinogen [Felis catus] 11 11 26.77824 
410980197 PREDICTED: pigment epithelium-derived factor [Felis 
catus] 
11 11 32.61391 
1126483442 PREDICTED: insulin-like growth factor-binding protein 
complex acid labile subunit [Felis catus] 
11 11 18.52941 
410952310 PREDICTED: serum paraoxonase/arylesterase 1 [Felis 
catus] 
10 10 34.64789 
410980361 PREDICTED: vitronectin [Felis catus] 10 10 27.99145 
1126474650 PREDICTED: alpha-2-antiplasmin isoform X2 [Felis 
catus] 
9 9 21.74797 
755801251 PREDICTED: zinc-alpha-2-glycoprotein [Felis catus] 9 9 36.64384 
1126452747 PREDICTED: fetuin-B isoform X2 [Felis catus] 9 9 27.82152 
1126444019 PREDICTED: complement component C8 alpha chain 
[Felis catus] 
9 9 17.28814 
290560143 Chain G, Crystal Structure Determination Of Cat (Felis 
Silvestris Catus) Hemoglobin At 2.4 Angstrom 
Resolution 
9 9 88.65248 
1126401809 PREDICTED: glutathione peroxidase 3 [Felis catus] 9 9 41.15044 
1101972906 TPA: globin C1 [Felis catus] 8 8 83.09859 
587002983 PREDICTED: plasma protease C1 inhibitor [Felis catus] 8 8 17.61252 
309951108 protein AMBP precursor [Felis catus] 8 8 30.11364 
1126441122 PREDICTED: GDH/6PGL endoplasmic bifunctional 
protein isoform X5 [Felis catus] 
8 8 10.66499 
410970733 PREDICTED: carboxypeptidase N subunit 2 [Felis catus] 8 8 16.45338 
6456731 immunoglobulin kappa light chain [Felis catus] 8 8 44.21488 
1126466567 PREDICTED: immunoglobulin lambda-like polypeptide 
5 [Felis catus] 
11 8 49.79253 
1126436027 PREDICTED: complement C1r subcomponent isoform 
X1 [Felis catus] 
7 7 10.61453 
755757807 PREDICTED: extracellular matrix protein 1 isoform X1 
[Felis catus] 
7 7 14.76868 
576864479 immunoglobulin G2 heavy chain consant region, partial 
[Felis catus] 
11 6 49.85075 
1126463686 PREDICTED: hyaluronan-binding protein 2 [Felis catus] 6 6 10.79137 
1126451434 PREDICTED: vitamin K-dependent protein S isoform X1 
[Felis catus] 
6 6 10.97923 
1126444017 PREDICTED: complement component C8 beta chain 
isoform X2 [Felis catus] 
6 6 10.49724 
410986627 PREDICTED: apolipoprotein A-II isoform X3 [Felis 
catus] 
6 6 60 
410982722 PREDICTED: apolipoprotein C-II [Felis catus] 6 6 70.29703 
586976411 PREDICTED: leucine-rich alpha-2-glycoprotein isoform 
X1 [Felis catus] 
6 6 17.85714 
587009725 PREDICTED: complement component C8 gamma chain 
isoform X1 [Felis catus] 
6 6 36.63366 
475392719 retinol binding protein 4 [Felis catus] 6 6 45.27363 
60392244 RecName: Full=Coagulation factor IX; AltName: 
Full=Christmas factor; Contains: RecName: 
Full=Coagulation factor IXa light chain; Contains: 
RecName: Full=Coagulation factor IXa heavy chain; 
Flags: Precursor 
5 5 11.58798 
410957470 PREDICTED: immunoglobulin J chain [Felis catus] 5 5 36.70886 
347666817 apolipoprotein B, partial [Felis catus] 5 5 7.359307 
3402543 IgG1 heavy chain, partial [Felis catus] 17 5 66.26866 
1126422662 PREDICTED: phosphatidylinositol-glycan-specific 
phospholipase D isoform X2 [Felis catus] 
5 5 6.785714 
2914011 IgM constant chain, partial [Felis catus] 6 5 43.7788 
410958740 PREDICTED: apolipoprotein M isoform X1 [Felis catus] 5 5 23.40426 
755821540 PREDICTED: complement C3-like, partial [Felis catus] 25 5 41.56545 
1080114020 CD5 antigen-like [Felis catus] 17 5 46.08696 
755813091 PREDICTED: properdin [Felis catus] 5 5 11.70213 
410950994 PREDICTED: tetranectin [Felis catus] 5 5 28.21782 
410987405 PREDICTED: carbonic anhydrase 2 [Felis catus] 5 5 22.69231 
325651605 immunoglobulin heavy chain variable region subgroup 3, 
partial [Felis catus] 
7 4 42.63158 
1126423477 PREDICTED: complement C2 isoform X2 [Felis catus] 4 4 5.125 
755741265 PREDICTED: thrombospondin-1 [Felis catus] 4 4 3.675214 
410957528 PREDICTED: platelet basic protein [Felis catus] 4 4 44.34783 
1126493169 PREDICTED: uncharacterized protein LOC109496317 
[Felis catus] 
4 4 9.649123 
566559804 transthyretin precursor [Felis catus] 4 4 51.36986 
587011734 PREDICTED: membrane primary amine oxidase [Felis 
catus] 
4 4 5.526316 
1126395104 PREDICTED: apolipoprotein C-II-like, partial [Felis 
catus] 
4 4 53.16456 
1126395712 PREDICTED: odorant-binding protein-like [Felis catus] 4 4 30.84112 
1126462331 PREDICTED: mannose-binding protein C [Felis catus] 4 4 21.8107 
755808301 PREDICTED: C-reactive protein [Felis catus] 4 4 25.56054 
1126480759 PREDICTED: apolipoprotein C-I [Felis catus] 3 3 35.89744 
325651527 immunoglobulin heavy chain variable region subgroup 1, 
partial [Felis catus] 
4 3 29.89691 
755776692 PREDICTED: carboxypeptidase N catalytic chain [Felis 
catus] 
3 3 7.158837 
544581253 mutant coagulation factor XII [Felis catus] 3 3 8.214286 
755789862 PREDICTED: LOW QUALITY PROTEIN: membrane 
primary amine oxidase [Felis catus] 
3 3 4.325033 
1126455929 PREDICTED: apolipoprotein C-III [Felis catus] 3 3 28 
586991757 PREDICTED: complement C1s subcomponent [Felis 
catus] 
3 3 5.179856 
586994526 PREDICTED: complement C1q subcomponent subunit A 
[Felis catus] 
2 2 13.46939 
755801558 PREDICTED: actin, cytoplasmic 1 [Felis catus] 7 2 23.2 
325651674 immunoglobulin heavy chain variable region subgroup 3, 
partial [Felis catus] 
3 2 16.66667 
410981199 PREDICTED: retina-specific copper amine oxidase [Felis 
catus] 
2 2 2.380952 
1080114022 CD5 antigen-like [Felis catus] 14 2 37.44589 
1126405556 PREDICTED: inter-alpha-trypsin inhibitor heavy chain 
H4 isoform X6 [Felis catus] 
43 2 58.68852 
587000359 PREDICTED: biotinidase isoform X2 [Felis catus] 2 2 5.075188 
755812005 PREDICTED: thymosin beta-4 [Felis catus] 2 2 29.54545 
755722705 PREDICTED: platelet factor 4-like [Felis catus] 2 2 16.34615 
47825211 alpha1-glycoprotein acid, partial [Felis catus] 10 2 41.91919 
1126440492 PREDICTED: fibulin-1 [Felis catus] 2 2 4.225352 
 
  
Supplementary Table 2. Relative intensity ratios (normalized to the internal standards) of each deregulated protein in the whole study population.   
Animal 
ID 
A1A  APOM  CPN1  ATIII Prothrombin CP A2AP TMSB4X  APOA2  PF4 C1 inhibitor Tetranectin IgHC IgK  IgL C8G 
CHF1 0.94 1.27 0.88 0.99 0.99 0.67 0.98 1.51 1.36 1.16 1.01 NA 0.78 0.78 0.8 0.97 
CHF2 1.25 1.2 NA 1.03 1.04 1.06 1.05 1.51 1.19 0.91 0.96 0.77 0.88 0.92 1 1.04 
CHF3 1.14 1.26 0.82 1.16 1.03 1.19 1.15 0.84 1.05 0.95 1.34 0.85 1.09 0.7 0.83 0.79 
CHF4 1.14 1.04 0.69 1.25 1.03 1.37 1.26 NA 0.97 0.79 1.51 0.91 0.86 0.95 0.97 1.11 
CHF5 0.82 0.95 NA 1.17 1.5 0.62 1.49 NA 1.36 2.18 1.06 1.2 0.69 1.79 0.78 1.17 
CHF6 1.12 1.25 1.25 1.21 1.1 1.23 1.27 NA 1.28 0.88 1.22 0.76 0.95 1 1.02 0.95 
CHF7 1.05 1.14 NA 1.25 1.06 1.1 1.1 1.2 0.94 1.18 1.33 0.84 1.07 0.71 0.84 0.44 
CHF8 0.93 0.88 0.94 0.92 0.93 0.98 1.31 0.8 0.8 0.9 0.89 1.64 1.04 0.87 1.14 1.08 
CHF9 0.91 0.87 1.43 0.84 0.99 0.93 0.96 NA 0.95 0.6 0.71 1.08 1.09 0.87 1.24 1.35 
CHF10 0.95 0.95 1.05 0.92 1.12 1.18 0.89 NA 0.91 1.28 1.05 0.81 0.89 0.87 0.91 1.08 
CHF11 0.96 1 NA 0.97 1.02 0.95 1.13 NA 1.08 0.69 1.04 1.09 0.87 0.93 0.81 1.06 
CHF12 0.98 0.91 1.17 1.16 1.05 1.12 1.15 NA 0.97 1.14 1.63 0.79 0.79 0.96 0.88 0.86 
CHF13 1.14 1.25 1.58 1.37 1.2 1.11 1.31 NA 2.11 1.36 1.58 0.89 0.73 0.6 0.52 0.82 
CHF14 1.07 1.07 0.99 0.96 1.03 1.19 0.95 NA 0.93 1.15 1.2 0.94 0.94 1.01 0.95 1.08 
CHF15 1.08 1.34 1.14 1.14 0.89 0.95 0.99 NA 0.77 1.71 1.49 0.6 0.69 0.65 0.64 0.96 
PrC1 1.24 1.37 0.92 1.14 1.16 1.1 1.13 0.46 1.68 0.87 1.24 NA 0.52 0.52 0.62 0.87 
PrC2 0.98 0.92 NA 1.04 0.86 1.05 1.01 0.71 0.76 0.63 1.26 1.2 1.1 1.07 0.99 1.08 
PrC3 0.91 0.93 0.84 1 1.01 1.03 1.11 1.03 1.02 1.49 1.15 1.31 1.14 0.84 1.02 0.96 
PrC4 0.86 1.01 1.03 0.87 0.96 0.8 1.03 NA 1.01 1.18 0.93 0.88 0.92 1.01 1.45 1.06 
PrC5 0.9 0.77 NA 0.88 1.03 0.75 0.96 NA 1.04 1.38 0.85 1.14 0.71 1.23 0.82 1.03 
Nor1 0.93 0.99 1.05 0.94 0.95 1.13 0.96 0.61 0.66 0.9 0.79 NA 1.62 1.1 1.35 1.1 
Nor2 1.07 1.17 NA 1.14 1.03 0.91 0.99 0.73 1.16 1 1.02 0.94 0.85 1.04 0.77 1.08 
Nor3 0.95 1.01 1.08 1.04 0.95 1.07 1.06 0.44 1.68 0.88 1.09 0.83 0.94 0.7 1.22 1.24 
Nor4 0.97 0.97 0.97 0.96 0.97 0.88 1.05 NA 0.87 0.76 0.79 0.94 1.09 1.11 1.02 1.07 
Nor5 0.95 1.01 0.76 0.93 1.01 0.84 1.02 NA 0.97 0.88 0.81 1.08 0.98 0.73 1.07 1.12 
 
 
              
Continued… 
Nor6 0.93 0.98 NA 0.99 0.98 0.97 0.96 NA 1.29 0.91 0.71 1.02 1.19 0.94 1.11 1.07 
Nor7 0.89 0.89 0.88 0.98 0.98 0.79 1.02 NA 0.65 0.78 0.87 1.34 1.19 1.32 1.04 1.14 
Nor8 0.85 0.78 0.76 0.75 0.98 0.88 0.94 NA 0.83 0.56 0.88 1.09 1.42 1.67 1.59 1.1 
Nor9 0.82 0.83 NA 0.86 0.94 0.91 1.02 NA 0.85 0.93 0.66 1.05 1.37 1.43 1.3 1.19 
Nor10 0.85 1.05 0.88 0.87 1.02 1.01 1 0.3 0.58 0.48 0.68 NA 1.09 1.13 1.21 1.06 
Nor11 1.11 1.09 0.89 1.16 0.92 0.98 0.92 0.2 0.69 0.52 0.83 NA 0.95 0.96 1.33 1 
Nor12 0.7 0.81 0.95 0.77 0.85 1 0.65 0.21 0.39 0.33 0.71 0.86 1.02 0.67 1.14 1.15 
Nor13 0.8 0.84 NA 0.84 1.16 0.88 1 1.38 0.44 1.57 0.99 0.91 0.86 1.38 1.19 0.55 
Nor14 0.99 0.9 0.47 1.04 0.93 0.95 1.18 NA 0.84 0.75 1.03 1.05 0.92 1.13 0.87 0.93 
Nor14 1.07 1.05 0.69 1.02 0.94 0.98 1.25 NA 0.86 0.87 1.25 0.89 0.81 0.9 0.71 1.05 
CHF, congestive heart failure; PrC, preclinical; Nor, healthy control; A1A, α-1 antitrypsin; APOM, apolipoprotein M; CPN1, carboxypeptidase 
N subunit 1;  AT III, antithrombin III; CP, ceruloplasmin; A2AP, α-2 antiplasmin; TMSB 4X, thymosin β-4; APOA2, apolipoprotein A-II; PF4, 
platelet factor 4; IgHC, immunoglobulin heavy chain; IgK, immunoglobulin kappa; IgL, immunoglobulin lambda; C8G, complement C8 gamma 
chain; NA, not available. 
 
 
